A Detroit man in his early 30s has become the first person in Michigan to receive Roctavian, the FDA-approved one-time gene therapy for severe hemophilia A, outside a clinical trial. The historic infusion took place Jan. 15 at the infusion and chemotherapy treatment center at Henry Ford Cancer–Detroit, where the patient spent several hours under tight surveillance from the hospital's hemophilia team as the gene therapy slowly dripped in. Hospital leaders say the case signals that cutting-edge cell and gene therapies are starting to move from research labs into routine clinical care in the region.
Henry Ford Health confirmed that the patient received valoctocogene roxaparvovec-rvox (ROCTAVIAN) and that the infusion itself ran for more than two hours. As reported by the Detroit Free Press, the health system is calling this the first Roctavian dose given in Michigan outside a clinical trial and says it has been building the infrastructure needed to deliver such therapies. BioMarin's online ROCTAVIAN doctor finder also lists Henry Ford clinician Dr. Philip Kuriakose among the physicians familiar with using the treatment.
Dr. Kuriakose, chief of hematology at Henry Ford Hospital and medical director of the Hemophilia and Thrombosis Treatment Center, told the Detroit Free Press, "Right now, things are going exactly as we expect. Things are going well." Hospital briefing materials estimate that a 175-pound patient would require about 30 vials of ROCTAVIAN. A company pricing sheet pegs each vial at roughly $94,745, putting the raw drug cost for a single treatment course at around $2.8 million before any hospital or professional fees are added.
How Roctavian Works and What It Costs
ROCTAVIAN works by delivering a working copy of the factor VIII gene into liver cells using a modified AAV5 viral vector, allowing the body to manufacture the missing clotting protein on its own instead of relying on regular infusions. The U.S. Food and Drug Administration approved the therapy in June 2023 as the first gene therapy for adults with severe hemophilia A, according to the FDA. Industry coverage reports that BioMarin set a U.S. list price of about $2.9 million for the one-time treatment, as noted by BioPharma Dive.
What Early Data Is Showing
Long-term follow-up from clinical trials suggests that a single infusion can lead to durable benefit for many people who receive it. Multi-year data have shown that average factor VIII activity often stays in the mild hemophilia range and that treated patients continue to have low annual bleed rates several years after dosing. In five-year follow-up from a pivotal study, BioMarin reported that about 81% of participants were still off prophylactic factor therapy, a statistic that helps explain why clinicians are watching the therapy closely despite its price tag, according to BioMarin. For comparison, the National Bleeding Disorders Foundation estimates that conventional prophylactic factor VIII treatment for people with severe hemophilia can run roughly $300,000 a year, a figure that frequently comes up when patients and payers weigh one-time gene therapies against standard care, according to the NBDF.
Henry Ford's Growing Role in Gene Therapy
Henry Ford's Hemophilia and Thrombosis Treatment Center participates in national research and outcomes initiatives in bleeding disorders, and the broader health system has been expanding training programs linked to cell and gene therapy. Federal trial listings show Henry Ford and Dr. Kuriakose among investigators on multi-site hemophilia studies, according to ClinicalTrials.gov. The hospital's own medical education pages highlight stem-cell and cell & gene therapy fellowships that are designed to build local expertise, as described by Henry Ford Health.
Specialists involved with Roctavian say that deciding to offer a commercial gene therapy infusion involves far more than signing off on the drug's price. Careful screening to determine who is eligible, close monitoring of liver function and other safety labs, and long-term follow-up are built into standard protocols. Recipients of ROCTAVIAN are asked to enroll in extended safety registries so that outcomes can be tracked over many years, and Henry Ford says this first Michigan patient will be followed as part of post-marketing surveillance and research, according to BioMarin.
